adbry
Eczema Treatments
adbry
Eczema Treatments

Adbry

Use Adbry® (tralokinumab-ldrm) as prescribed to help treat moderate to severe eczema (atopic dermatitis) by targeting interleukin-13 (IL-13), a key driver of chronic skin inflammation, to reduce itching, redness, and flare frequency.
Adbry is a biologic medication that blocks interleukin-13 (IL-13), a key driver of inflammation in eczema. It helps reduce redness, itching, and flare-ups in moderate to severe eczema.
It is suitable for adults with moderate to severe eczema who have not responded adequately to topical or other systemic treatments.
Patients often see significant improvement within the first 4–6 weeks of treatment.
Adbry is prescribed for adults with moderate to severe eczema who have not responded adequately to topical treatments or when other therapies are not appropriate. It is administered as a subcutaneous injection under clinician guidance. See pricing details here.

Real patients, real results

How effective is Adbry

Clinically proven results

Meaningful and sustained improvement in eczema severity and itch with ongoing treatment.*
Clinical studies show that Adbry helps reduce eczema symptoms and flare frequency, with many patients achieving clearer skin and improved quality of life over time.
*In clinical trials, patients treated with Adbry experienced significant improvement in eczema severity and itch reduction compared to placebo over 16 weeks.
Adbry should be used only as prescribed. For more details, see Important Safety Information.

How DermOnDemand Works

Common Question

Common side effects include injection site reactions and mild upper respiratory symptoms, such as a sore throat or cough.
Adbry is given as a subcutaneous injection, typically every two weeks after an initial loading dose.